FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040429940> ?p ?o ?g. }

• W2040429940 endingPage "1809" @default.
• W2040429940 startingPage "1807" @default.
• W2040429940 abstract "To the Editor: The World Health Organization Polio Eradication Initiative has reduced to 4 the number of countries with endemic transmission of wild polioviruses and has reported the widespread circulation of polioviruses that have evolved from attenuated vaccine (oral poliovirus vaccine [OPV]), so-called vaccine-derived polioviruses (VDPVs) (1,2). VDPVs can reportedly replicate in immunocompromised persons, in whom they produce paralysis, and can spread to contacts and produce paralytic polio in immunocompetent but incompletely immunized persons; these viruses can even cause some polio outbreaks in areas with a low level of vaccination coverage (2). When VDPVs are detected, a careful follow-up of VDPV cases and contacts is essential if spread is to be avoided. Because point mutations or recombination events have been associated with reversion to neurovirulence transmission and thus a greater probability of outbreaks (2), meticulous molecular studies of the detected strains are recommended.Spain progressively adopted vaccination with OPV for children in 2004. As a consequence, the incidence of vaccine-like poliovirus detection in recently vaccinated children, which was relatively common up to that time (51 isolates in 2003) (3), began to decrease (15 isolates in 2004 and none in 2005 except the case described here). In July 2005, a 14-month-old boy from Morocco with residual paralysis and major histocompatibility class II immunodeficiency was reported through the Spanish Acute Flaccid Paralysis Surveillance System. The patient had received 2 OPV doses at birth and at 6 months of age in Morocco; 8 months later, meningoencephalitis developed. The case was immediately considered suspicious and was therefore monitored at least monthly until the boy died. Sampling was conducted, coinciding with his visits to the hospital to receive therapy with immunoglobulin (γ globulin 0.5 g/kg). His contacts were studied, environmental surveillance was conducted, and molecular analysis of all detected viruses was performed. Laboratory methods for virus detection and characterization, including 10 new reverse-transcription–PCRs designed to cover the entire genome, are detailed in the Table.TableLaboratory methods used for study of vaccine-derived poliovirus case, Spain, 2005*Serotype 2 VDPVs were detected in all 10 stool samples of the patient with residual paralysis for 6 months, until he died, and in 3 of the 7 family contacts analyzed (father and 2 brothers, 11 and 13 years of age, none with confirmed previous vaccination). One of the contacts, considered immunocompetent, shed virus for 216 days (5 fecal samples in which 5 complete genomes were obtained and 1 additional fecal sample in which virus capsid protein l [VP1] could be amplified); a stool sample collected on day 284 was negative. Technical problems delayed sewage sampling. When sewage from the area in which the patient and positive contacts lived was sampled on February 8, 2006, no polioviruses were detected; however, an echovirus 30 was detected. Poliovirus viral load fluctuated (106–109 copies/mL in the paralysis-affected person), decreasing after each immunoglobulin therapy dose (Figure 1 in the Technical Appendix). The corresponding level was <105 in the contacts. The highest value of viral load was recorded in the patient’s final sample, taken before he died. Homology of the VP1 gene with respect to the original vaccine PV2 fluctuated from 97.8% to 98.6% in the case samples but remained constant (98.4%) in the contact samples (Figure 1 in the Technical Appendix). All studied polioviruses featured the following nucleotide substitutions in the 5′ untranslated region: G309A, T344C, T355C, T398C, A481G, T500C, and T743C (Figure 2 in the Technical Appendix). Furthermore, the final sample from the patient had A476C, G505T, T588A, and A738C. Several nucleotide substitutions detected in VP1–4 were common to all samples (Figure 2 in the Technical Appendix); 5 resulted in amino acid changes, including T2909C (VP1 I143T) and G3277A (VP1 V266I). All samples contained 2 noncontiguous recombination fragments Sabin 2/Sabin 1 in the nonstructural genes, including the entire 3C gene and the 3′ half of the 3D-pol (Figure 2 in the Technical Appendix) as in other reports (7–10). Both fragments, when compared with C species enterovirus, were closely related to Sabin 1 (99.6% and 97.9%, respectively). Specific nucleotide and amino acid comparisons among the isolates are detailed in Figure 3 in the Technical Appendix.According to the proposed classification (2), all the detected viruses were iVDPVs (isolated from immunocompromised patients) that spread only to close contacts because they were not detected in local sewage. If we assume that the greater the amount of viral excretion in feces that occurs, the higher number of replicating polioviruses (as well as the potential for greater genetic diversity), the patient had a more active infection (that responded to the therapy) than did the contacts. Fluctuation in homology to the parental OPV strain might be due not only to the calculation method (calculation was made on the basis of the majority-base call at each chromatogram position, and case sequences presented many mixed nucleotide positions) but also to immunotherapy. Treatment appeared to have decreased virus replication, probably by its action mainly on species with greater fitness and higher replication rates (those that were more similar to the original Sabin strain). As a consequence, treatment might produce a bottleneck that unmasked more divergent species. Both the case and contact strains had intertypic Sabin 1/Sabin 2 recombination in nonstructural genes and also shared most of the nucleotide and amino acid substitutions. However, pathologic changes occurred only in the patient whose immunologic mechanisms were affected and whose viral load was consequently much higher. A recent report (1) suggests that VDPVs can emerge in any country that uses OPV with insufficient vaccine coverage. In a polio-free IPV-user country, poliomyelitis can arise and spread to contacts who are not properly vaccinated. In the case we present here, the high level of vaccination coverage in Spain and the rapid control of close contacts achieved through the surveillance and control programs prevented virus spread. In the global pre-eradication phase, countries are recommended to change vaccination from OPV to IPV. However, IPV-adopting countries commonly share borders with OPV-adopting countries and residents may travel back and forth; thus, although the probability of VDPV circulation decreases, it does not reduce to zero. Therefore, active surveillance, rapid classification of isolates, and molecular characterization of the virus are essential." @default.
• W2040429940 created "2016-06-24" @default.
• W2040429940 creator A5013937606 @default.
• W2040429940 creator A5019826487 @default.
• W2040429940 creator A5024596144 @default.
• W2040429940 creator A5029501365 @default.
• W2040429940 creator A5044066051 @default.
• W2040429940 creator A5076946367 @default.
• W2040429940 creator A5077737606 @default.
• W2040429940 creator A5085516891 @default.
• W2040429940 date "2008-11-01" @default.
• W2040429940 modified "2023-10-01" @default.
• W2040429940 title "Paralysis Case and Contact Spread of Recombinant Vaccine–derived Poliovirus, Spain" @default.
• W2040429940 cites W2003295932 @default.
• W2040429940 cites W2019839124 @default.
• W2040429940 cites W2026125064 @default.
• W2040429940 cites W2032250321 @default.
• W2040429940 cites W2073154087 @default.
• W2040429940 cites W2090194796 @default.
• W2040429940 cites W2107787885 @default.
• W2040429940 cites W2117691753 @default.
• W2040429940 cites W2134693843 @default.
• W2040429940 cites W2157871996 @default.
• W2040429940 doi "https://doi.org/10.3201/eid1411.080517" @default.
• W2040429940 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2630745" @default.
• W2040429940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18976579" @default.
• W2040429940 hasPublicationYear "2008" @default.
• W2040429940 type Work @default.
• W2040429940 sameAs 2040429940 @default.
• W2040429940 citedByCount "24" @default.
• W2040429940 countsByYear W20404299402012 @default.
• W2040429940 countsByYear W20404299402013 @default.
• W2040429940 countsByYear W20404299402014 @default.
• W2040429940 countsByYear W20404299402015 @default.
• W2040429940 countsByYear W20404299402016 @default.
• W2040429940 countsByYear W20404299402017 @default.
• W2040429940 countsByYear W20404299402018 @default.
• W2040429940 countsByYear W20404299402019 @default.
• W2040429940 countsByYear W20404299402020 @default.
• W2040429940 countsByYear W20404299402023 @default.
• W2040429940 crossrefType "journal-article" @default.
• W2040429940 hasAuthorship W2040429940A5013937606 @default.
• W2040429940 hasAuthorship W2040429940A5019826487 @default.
• W2040429940 hasAuthorship W2040429940A5024596144 @default.
• W2040429940 hasAuthorship W2040429940A5029501365 @default.
• W2040429940 hasAuthorship W2040429940A5044066051 @default.
• W2040429940 hasAuthorship W2040429940A5076946367 @default.
• W2040429940 hasAuthorship W2040429940A5077737606 @default.
• W2040429940 hasAuthorship W2040429940A5085516891 @default.
• W2040429940 hasBestOaLocation W20404299401 @default.
• W2040429940 hasConcept C104317684 @default.
• W2040429940 hasConcept C141071460 @default.
• W2040429940 hasConcept C159047783 @default.
• W2040429940 hasConcept C203014093 @default.
• W2040429940 hasConcept C2522874641 @default.
• W2040429940 hasConcept C2779618896 @default.
• W2040429940 hasConcept C2779631682 @default.
• W2040429940 hasConcept C2910216234 @default.
• W2040429940 hasConcept C40767141 @default.
• W2040429940 hasConcept C4870876 @default.
• W2040429940 hasConcept C54355233 @default.
• W2040429940 hasConcept C71924100 @default.
• W2040429940 hasConcept C86803240 @default.
• W2040429940 hasConceptScore W2040429940C104317684 @default.
• W2040429940 hasConceptScore W2040429940C141071460 @default.
• W2040429940 hasConceptScore W2040429940C159047783 @default.
• W2040429940 hasConceptScore W2040429940C203014093 @default.
• W2040429940 hasConceptScore W2040429940C2522874641 @default.
• W2040429940 hasConceptScore W2040429940C2779618896 @default.
• W2040429940 hasConceptScore W2040429940C2779631682 @default.
• W2040429940 hasConceptScore W2040429940C2910216234 @default.
• W2040429940 hasConceptScore W2040429940C40767141 @default.
• W2040429940 hasConceptScore W2040429940C4870876 @default.
• W2040429940 hasConceptScore W2040429940C54355233 @default.
• W2040429940 hasConceptScore W2040429940C71924100 @default.
• W2040429940 hasConceptScore W2040429940C86803240 @default.
• W2040429940 hasIssue "11" @default.
• W2040429940 hasLocation W20404299401 @default.
• W2040429940 hasLocation W20404299402 @default.
• W2040429940 hasLocation W20404299403 @default.
• W2040429940 hasLocation W20404299404 @default.
• W2040429940 hasLocation W20404299405 @default.
• W2040429940 hasOpenAccess W2040429940 @default.
• W2040429940 hasPrimaryLocation W20404299401 @default.
• W2040429940 hasRelatedWork W108554964 @default.
• W2040429940 hasRelatedWork W2050179120 @default.
• W2040429940 hasRelatedWork W2085535385 @default.
• W2040429940 hasRelatedWork W2150446667 @default.
• W2040429940 hasRelatedWork W2167550865 @default.
• W2040429940 hasRelatedWork W2340057234 @default.
• W2040429940 hasRelatedWork W2385315192 @default.
• W2040429940 hasRelatedWork W2998929374 @default.
• W2040429940 hasRelatedWork W4385491733 @default.
• W2040429940 hasRelatedWork W2769038553 @default.
• W2040429940 hasVolume "14" @default.
• W2040429940 isParatext "false" @default.
• W2040429940 isRetracted "false" @default.
• W2040429940 magId "2040429940" @default.

• next